Louisiana Initial Medical Licensure Program
The purpose of this course is to educate prescribers on best practices for the safe prescribing of controlled substances, including opioid analgesics. The course focuses on regulatory and legal framework, current best practices for prescribing controlled substances, pharmacologic (nonopioid and opioid analgesics) and non-pharmacologic therapies for pain management, diversion and treatment of substance use disorders.
This course is designed for all physicians and health care providers involved in the treatment and monitoring of patients prescribed controlled substances.
- Explain the purpose, role, and need for the Controlled Substances Act (CSA) as it relates to clinical practice.
- Explain the similarities and differences between the five (5) DEA schedules for controlled substances.
- Describe the key steps recommended for the responsible prescribing of controlled substances.
- Describe pharmacological treatment options for treating pain, anxiety disorder, insomnia, narcolepsy, and attentiondeficit hyperactivity disorder.
- Describe the fundamental concepts of pain management, including definitions and mechanisms of pain.
- Identify the range of therapeutic options for managing pain, including non-pharmacologic approaches and pharmacologic (non-opioid and opioid analgesics) therapies.
- Explain how to integrate opioid analgesics into a pain treatment plan individualized to the needs of the patient, including counseling patients and caregivers about the safe use of opioid analgesics.
- Describe how to safely and effectively manage patients on opioid analgesics in the acute and chronic pain settings, including assessing, initiating therapy, titrating, ongoing and discontinuing use.
- Describe at least four (4) practices clinicians can use to minimize diversion of controlled substances.
- Identify the six (6) approved pharmacotherapies for treating alcohol and opioid use disorders.
Paul J. Christo, MD, MBA
Director, Multidisciplinary Pain Fellowship Program
Associate Professor of Anesthesiology and Critical Care Medicine
The Johns Hopkins University School of Medicine
Melissa B. Weimer, DO, MCR, FASAM
Chief of Behavioral Health and Addiction Medicine
Saint Peter’s Health Partners
Clinical Assistant Professor of Medicine
Oregon Health and Science University
Oregon Health and Science University
Braun Medical Media
Dove Medical Communications
Joseph J. McGurrin
DISCLOSURE OF INTEREST:
In accordance with the ACCME Standards for Commercial Support of CME, InforMed implemented mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.
InforMed is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
InforMed designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This InforMed designates this enduring material for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Initial Licensees with a CDS license in Louisiana must complete a one-time requirement of at least three (3) hours of Board approved CME on best practices for prescribing controlled substances, drug diversion, addiction treatment and treatment of chronic pain.
- 3.00 AMA PRA Category 1 Credit™
This course is offered through InforMed.
To take this course you will be redirected to InforMed's website. You must login or create an account with InforMed in order to complete this activity.
Mocingbird works to provide curated, high quality content to our users. Have a suggestion? Want to partner with us? Get in touch!
Controlled Substances, Prescribing, Pharmacology, Pain Management, Schedule II Drugs, Substance Use Disorder